Clinical Trials Logo

Lenvatinib clinical trials

View clinical trials related to Lenvatinib.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06435013 Completed - Clinical trials for Hepatocellular Carcinoma

Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

Start date: December 1, 2023
Phase:
Study type: Observational

Previous studies had suggested hepatic arterial infusion chemotherapy (HAIC) combined with immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs had promising anti-tumor activity in unresectable hepatocellular carcinoma (HCC). Two kinds of anti-angiogenic drugs (tyrosine kinase inhibitors [lenvatinib] and anti-VEGF antibody [bevacizumab]) were applied in first-line treatment of unresectable HCC. However, little is known about the difference of efficacy and safety between lenvatinib (LenHAP) or bevacizumab (BevHAP) combined with ICIs and HAIC in unresectable HCC.